Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies
Status:
Active, not recruiting
Trial end date:
2022-11-02
Target enrollment:
Participant gender:
Summary
This phase II trial will examine whether genetically reprogramming a patient's disease
fighting white blood cells may build an immune response to kill cancer cells that express the
NY-ESO-1 protein. In this study, this genetic therapy will be given during a stem cell
transplant along with a vaccine therapy. The vaccine will be made using the NY-ESO-1 protein
and may help to stimulate the engineered immune response to tumor cells.